Phase I Study of the Safety of Replication-Defective Herpes Simplex Virus-2 Vaccine, HSV529, in Adults Aged 18 to 40 Years With or Without HSV Infection

Trial Profile

Phase I Study of the Safety of Replication-Defective Herpes Simplex Virus-2 Vaccine, HSV529, in Adults Aged 18 to 40 Years With or Without HSV Infection

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Mar 2017

At a glance

  • Drugs ACAM 529 (Primary)
  • Indications Herpes simplex virus type 2 infections
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 02 Dec 2016 Planned End Date changed from 1 Nov 2016 to 1 Nov 2017.
    • 02 Dec 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top